Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

H-22411: BOTOX® for Peyronie's Disease

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by Baylor College of Medicine
Sponsor:
Collaborator:
Allergan
Information provided by (Responsible Party):
Mohit Khera, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT00812838
First received: December 18, 2008
Last updated: April 30, 2014
Last verified: April 2014

December 18, 2008
April 30, 2014
February 2009
July 2015   (final data collection date for primary outcome measure)
Change in penile curvature [ Time Frame: End of treatment at 16 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00812838 on ClinicalTrials.gov Archive Site
  • Improvements in penile blood flow [ Time Frame: End of participation at 16 weeks ] [ Designated as safety issue: No ]
  • Reduction in penile plaque size as seen on ultrasound [ Time Frame: End of participation at 16 weeks ] [ Designated as safety issue: No ]
  • Changes in IIEF (International Index of Erectile Function) scores [ Time Frame: End of participation at 16 weeks ] [ Designated as safety issue: No ]
  • Improvements in penile blood flow [ Time Frame: End of participation at 16 weeks ] [ Designated as safety issue: No ]
  • Reduction in penile plaque size as seen on ultrasound [ Time Frame: End of participation at 16 weeks ] [ Designated as safety issue: No ]
  • Changes in IIEF scores [ Time Frame: End of participation at 16 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
H-22411: BOTOX® for Peyronie's Disease
The Efficacy of Botulinum Toxin Type a in Treating Peyronie's Disease

Peyronie's disease is a condition in which a plaque, or hard lump, forms on the penis. It causes hardened tissue, pain, and an abnormal bending in the penis. These symptoms are more severe during an erection. Significant bending of the penis can result in pain, poor erections, and an inability to engage in sexual intercourse.

This disease affects about 3% of the male population. The average age of onset of this disease is 57 years old. The cause of the disease is unknown. However, many believe that it may be due to trauma to the penis (such as injury or extremely vigorous sexual activity).

Treatments for this disease have been limited and often unsuccessful. The goal of treatment is to reduce pain and maintain sexual function. Oral medicines that prevent plaque formation and promote plaque breakdown have not been effective. Many patients with the disease will require injections of medicines directly into the plaque. These injections have been used for over 50 years in the treatment of major Peyronie's disease. The disease often resolves on its own without treatment. Surgery may be performed to remove hardened tissue in the penis. However, surgery is not done during the first 12 months of the disease.

There are 2 phases of the disease: the active phase and the inactive phase. The active phase usually occurs during the first 12 months of the disease. The stabilization of the plaque is known as the inactive phase. We are inviting men with stable disease to take part in this study which will test BOTOX® versus a placebo (a placebo contains no medicine).

This will be a randomized, placebo-controlled, cross-over, single-center trial. Study drug is Botulinum toxin type A (BOTOX®). Subjects who meet the inclusion criteria for the study will be randomized to either the treatment or placebo arm.

  • Treatment: Injection solution will consist of 100 units of BOTOX® in 10 cc of preservative free normal saline, or
  • Placebo: Injection solution will consist of 10 cc preservative free normal saline.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Peyronie's Disease
  • Drug: 100 units of BOTOX®
    Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque
    Other Name: Botulinum Toxin Type A, Purified Neurotoxin Complex, Clostridium botulinum type A neurotoxin complex
  • Other: Preservative free normal saline
    Approximately 20 to 30 injections of 10cc of preservative free normal saline given with a 20 gage needle directly into the penile plaque
  • Experimental: BOTOX®
    Injection solution will consist of 100 units of BOTOX® in 10 cc of preservative free normal saline
    Intervention: Drug: 100 units of BOTOX®
  • Placebo Comparator: Normal saline
    Injection solution will consist of 10 cc preservative free normal saline
    Intervention: Other: Preservative free normal saline
Khera M, Boone TB, Smith CP. Botulinum toxin type A: a novel approach to the treatment of recurrent urethral strictures. J Urol. 2004 Aug;172(2):574-5. No abstract available.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
20
January 2016
July 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects with stable Peyronie's plaques.
  • Males at least 18 years of age
  • Must give informed consent.

Exclusion Criteria:

  • Subjects in the active phase of Peyronie's disease.
  • Subjects with less than 1 year history of Peyronie's disease.
  • Subjects taking oral medications for Peyronie's disease which include Trentol, Viagra, vitamin E, colchicines, L-arginine, and tamoxifen. There will be a 2 week wash-out period if patients are on these medications.
  • Subjects with more than 1 penile plaque will be excluded from the study.
  • Subjects with calcified plaques demonstrated by ultrasound will be excluded from the study.
  • Known allergy or sensitivity to any components of the study medication (botulinum toxin A), anesthetics, or any other product associated with the treatment and general study procedures.
  • Any medical condition or neuromuscular disorder that may put the patient at increased risk with exposure to botulinum toxin A (BTX-A), including myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis.
  • Patient taking aminoglycosides or any drug known to interfere with neuromuscular transmission.
  • Patient has hemophilia or other clotting factor deficiencies or disorders that cause bleeding diathesis.
  • Patient must not be taking aspirin, non-steroidal anti-inflammatory drugs, or Coumadin for 7 or more days prior to Botox injection.
  • Episode of unstable angina pectoris, myocardial infarction, transient ischemic attack, or cerebrovascular accident within the past 6 months.
Male
18 Years and older
No
Contact: Sharon Harrison 713-798-2240 sharons@bcm.edu
United States
 
NCT00812838
11-07-40-04
No
Mohit Khera, Baylor College of Medicine
Mohit Khera
Allergan
Principal Investigator: Mohit Khera, MD, MBA Baylor College of Medicine
Baylor College of Medicine
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP